biotech / news / / Reuters
Zealand plans to invest $800 million in research over the next five years.
Petrelintide targets a different hormone pathway than Wegovy or Zepbound, aiming for fewer side effects.
KEY POINTS
- Zealand plans to invest about $800 million in research over the next five years.
- Zealand's cash position was DKK 14.5 billion at the end of March 2024.
- Zealand's 2026 operating expense guidance remains unchanged despite buyback and new spending plans.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →